Alzheimer's Foundation of America
Select text size: a | a | a
 

Clinical Trials

Find a Trial

To find a trial, please view the list below. Also visit www.clinicaltrials.gov.

Search by State:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ALABAMA

Location: Birmingham
University of Alabama at Birmingham- Division of Preventive Medicine

Trial Title and Description:
Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)- The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Isabelle Joffrion
205-934-9502
ijoffrion@dopm.uab.edu

Back to Top

Location: University of Alabama at Birmingham

Trial Title and Description: Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
The purpose of this study is to test if bapineuzumab is effective and safe in treating Alzheimer’s Disease. In patients with Alzheimer’s, plaques are formed in the brain that are thought to be related to the progression of the disease. It is hoped that bapineuzumab will attach to the protein that forms the plaques and help the body remove it.

Enrollment Status: Actively recruiting

Study Dates: started recruiting November 2010 Expected Completion:

Condition: Alzheimer’s Disease
Age Eligibility: 50-88 years of age
Gender Eligibility: Both
Enrollment Goal: 1,000
Clinical Identifier: NCT00574132
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Pfizer

Contact Information:
Name: Sherer Thomson
Phone: 205-996-5987

Back to Top

ALASKA

Location: Anchorage
Alaska Regional Hospital

Trial Title and Description:
Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Judith Link
907-264-1579
judith.link@healthcare.com

Back to Top

Location: Anchorage
Providence Alaska Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kathleen W. Shue
907-261-3109
kwilsack@provak.org

Back to Top

ARIZONA

Location: Phoenix
Banner Alzheimer’s Institute

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation

Contact Information:
Sarah Medina-Rodriguez
602-839-4640
sarah.medina-rodriguez@bannerhealth.com
For more information, visit www.gapstudy.com

Back to Top

Location: Phoenix

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Banner Alzheimer’s Institute
Lisa Cooper
602-239-6920
www.KiokuStudy.com

Back to Top

Location: Phoenix
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Flitman (for zip code 85013)
877-379-3718

Pierre Tariot (for zip code 85006- Not yet recruiting)
602-239-6920

Jeffrey Gitt (for zip code 85050)
602-288-4673

Back to Top

Location: Phoenix
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Flitman
877-379-3718

Back to Top

Location: Sun City
Banner Sun Health Research Institute

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Elizabeth Karoll
623-974-7394
beth.karoll@bannerhealth.com

Back to Top

Location: Sun City
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Maninder Kahlon
877-379-3718

Back to Top

Location: Tucson
University of Arizona (Arizona Health Sciences Center)

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Susan Merski
520-626-4296
smerski@email.arizona.edu
For more information, visit www.gapstudy.com

Back to Top

Location: Tucson

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Northwest NeuroSpecialists, PLLC
Dawn Brown
520-742-1833
www.KiokuStudy.com

Back to Top

Location: Tucson
University of Arizona

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Marjorie Baldwin
520-626-4296
baldwinm@u.arizona.edu

Geoffrey Ahern

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top

Location: Call for details

Trial Title and Description: Open-Label Extension Assessing Long Term Safety of Rosiglitazone In Subjects with Mild To Moderate Alzheimer's Disease-

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: February 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase 2
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
877-379-3718

Back to Top

ARKANSAS
CALIFORNIA

Location: Chula Vista
University of California, San Diego-Chula Vista

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Clydene Nee
858-622-5747

Back to Top

Location: Fresno
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline 

Contact Information:
David Margolin (for zip code 93720)
Justine Kent (for zip code 93720)
877-379-3718

Back to Top

Location: Glendale
Glendale Memorial Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Mary Eichenhofer
818-409-7653

Back to Top

Location: Irvine
University of California, Irvine – Alzheimer’s Disease Research Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Beatriz Yanez
949-824-3250
byanez@uci.edu

Back to Top

Location: Irvine
University of California, Irvine

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Catherine McAdams-Ortiz
949-824-8726
cmcadams@uci.edu

Ruth Mulnard

Back to Top

Location: La Jolla
University of California, San Diego

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Elizabeth Ortega
858-677-1567
ejortega@ucsd.edu
For more information, visit www.gapstudy.com

Back to Top

 

Location: La Jolla
University of California, San Diego

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Mary Pay
858-622-5804
mpay@ucsd.edu

Judith Rivera
858-622-5807
jrivera@ucsd.edu

David Weisman

Back to Top

Location: La Jolla
University of California, San Diego

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Clydene Nee
858-622-5747

Back to Top

Location: La Mesa
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jorge Porras
877-379-3718

Back to Top

Location: Loma Linda
VA Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kimberly A. Bluff
909-558-3107
bluffk@lom.med.va.gov

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease

The purpose of this Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due Alzheimer’s Disease (AD) or mild AD who test positive for amyloid plaque.

Enrollment Status: Recruiting

Study Dates: Start: March 2012 Expected Completion: February 2014

Condition: Alzheimer's disease
Age Eligibility: 55 years or older
Gender Eligibility: Male or Female
Enrollment Goal: 129
Clinical Identifier: NCT01561430
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD)

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start: March 2013 Expected Completion: January 2015

Condition: Alzheimer's disease
Age Eligibility: 66-90
Gender Eligibility: Male or Female
Enrollment Goal: 480
Clinical Identifier: NCT01741194
Study Phase: Phase 2/3
Study Type: Interventional

Sponsor: Accera, Inc.

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start: November 2012 Expected Completion: July 2015

Condition: Alzheimer's disease
Age Eligibility: 18-89
Gender Eligibility: Male or Female
Enrollment Goal: 500
Clinical Identifier: NCT01689233
Study Phase: Phase 3
Study Type: Interventional

Sponsor: TauRx Therapeutics Ltd

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH)

The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease (AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score.

Enrollment Status: Recruiting

Study Dates: Start: November 2012 Expected Completion: January 2017

Condition: Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 1960
Clinical Identifier: NCT01739348
Study Phase: Phase 2/3
Study Type: Interventional

Sponsor: Merck

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
VAMC Long Beach

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Francoise M. Toussaint-Jones
562-826-5755

Back to Top

Location: Los Angeles
University of Southern California

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Mauricio Becerra
323-442-7534
mjbecerr@usc.edu
For more information, visit www.gapstudy.com

Back to Top

Location: Los Angeles
University of California, Los Angeles

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Jenny Bardens
310-794-6191
jbardens@mednet.ucla.edu

John Ringman

Back to Top

Location: Los Angeles
University of California

Trial Title and Description: Depression in Alzheimer's Disease-

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication Sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Enrollment Status: Recruiting

Study Dates: Start: July 2004

Condition: Alzheimer's disease, Depression
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2, 3
Study Type: Interventional

Sponsor: National Institute of Mental Health (NIMH)

Contact Information:
Shirley Sian
323-442-7600
sian@usc.edu

Back to Top

Location: Los Angeles
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
David Trader
877-379-3718

Back to Top

Location: Newport Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Philip O'Carroll
877-379-3718

Back to Top

Location: Northridge
Northridge Hospital Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Diane M. Killian
818-885-5458

Back to Top

Location: Oceanside
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Valentin Isacescu
877-379-3718

Back to Top

Location: Orange
University of California, Irvine – Brain Imaging Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Azita Adami
714-456-8517
aadami@uci.edu

Back to Top

Location: Palo Alto
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Natalie Rasgon
877-379-3718

Back to Top

Location: Rancho Mirage
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard Hubbard
760-773-9117

Back to Top

Location: Redondo Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
George Rederich
877-379-3718

Back to Top

Location: Reseda
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Robert Hutchman
877-379-3718

Back to Top

Location: Sacramento
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
William Au
877-379-3718

Back to Top

Location: San Diego
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
John Doria
877-379-3718

Back to Top

Location: San Francisco
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jerome Goldstein
877-379-3718

Back to Top

Location: Santa Rosa
Santa Rosa Memorial Hospital Regional CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kris Haratigan
707-521-3820

Back to Top

Location: Sherman Oaks
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jose Schuster
877-379-3718

Back to Top

Location: Torrance
Harbor UCLA Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Marie Jackson
310-222-5339

Back to Top

Location: Upland

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Arlene J. Katchem
909-373-0381

Back to Top

Location: Call for details

Trial Title and Description: Raloxifene for Women with Alzheimer's Disease-

The purpose of this study is to determine whether Raloxifene, a selective estrogen receptor modulator, improves cognitive function in women with Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: August 2006

Condition: Alzheimer's disease
Age Eligibility: 60 and above
Gender Eligibility: Female
Enrollment Goal: 72
Clinical Identifier: NCT00368459
Study Phase: Phase 2
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Victor Henderson
650-498-5232
asye@stanford.edu

Sheryl Lynch
317-278-8307
slynch@iupui.edu

Back to Top

COLORADO

Location: Denver
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Leslie Moldauer
877-379-3718

Back to Top

Location: Denver
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jack Klapper
877-379-3718

Back to Top

Location: Fort Collins
Rocky Mountain CC/ Poudre Valley Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Linda M. Hadlow
970-495-7322

Back to Top

CONNECTICUT

Location: Darien
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Bart Sloan
877-379-3718

Back to Top

Location: Fairfield
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Kenneth Siegal
877-379-3718

Back to Top

Location:  Institute for Neurodegenerative Disorders – New Haven, CT.

Trial Title and Description:A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Enrollment Status: Active

Study Dates:  Nov. 2012 (41 months)

Condition: Alzheimer disease or MCI
Age Eligibility
: 50-90
Gender Eligibility: male and female
Enrollment Goal: 800 subjects
Clinical Identifier
: BAN2401
Study Phase: Phase 2
Study Type: Investigational drug study

Sponsor: Eisai Inc.

Contact Information:
Barbara Fussell RN
800-401-6067
bfussell@indd.org

Back to Top

Location: New Haven
Yale University

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Amanda Benincasa
203-764-8100
Amanda.Benincasa@yale.edu
For more information, visit www.gapstudy.com

Back to Top

Location: New Haven
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Christopher Van Dyck
877-379-3718

Back to Top

DISTRICT OF COLUMBIA

Location: Washington, DC
Georgetown University

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Anne Schultz
202-687-8800
ajs235@georgetown.edu

Back to Top

Location: Washington, DC
Howard University

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Ezenwanyi Ahaghotu
202-865-1972
eahaghotu@howard.edu

Back to Top

Location: Washington, DC
DC United MBCCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Dionne Thorne
202-865-5398

Back to Top

Location: Washington , DC
George Washington University Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility:
60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Maria-Lourdes Caparas
202-496-6464

Back to Top

Location: Washington , DC
Silbley Memorial Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Sheila Evans
202-243-2320
sevans@sibley.org

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top

Location: Call for details

Trial Title and Description: PET Scanning [11C] MeS-IMPY to Measure Amyloid in Brain-

This study will use positron emission tomography (PET) to measure a protein called amyloid in the brains of healthy volunteers and people with Alzheimer's disease. The tracer used in this study is a research drug called [11C] MeS-IMPY.

Enrollment Status: Recruiting

Study Dates: Start: December 2006

Condition: Alzheimer's disease, Neurodegenerative disease, Dementia
Age Eligibility: Healthy subjects: 18-80
Alzheimer's diseases: 50-80
Gender Eligibility: Both
Enrollment Goal: 15
Clinical Identifier: NCT00407576
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute of Mental Health

Contact Information:
Patient Recruitment and Public Liaison Office
800-411-1222

Back to Top

FLORIDA

Location: Sunrise

Trial Title and Description: Efficacy and Safety of MK-7622 as Adjunct Therapy to Donepezil in Participants With Alzheimer's Disease (MK-7622-012)

Enrollment Status: Enrolling
Study Dates: Start: October 2013 End: August 2017
Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 55-85 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 830
Clinical Identifier: NCT01852110
Study Phase: II
Study Type: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Sponsor: Merck
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild-Moderate Alzheimer's Disease Treated With Donepezil

Enrollment Status: Enrolling
Study Dates: Start: January 2014 End: January 2016
Condition: Mild to Moderate Alzheimer's Disease
Age Eligibility: 50 years and older
Gender Eligibility: Male/Female
Enrollment Goal: 840
Clinical Identifier: NCT02006641
Study Phase: III
Study Type: Interventional
Sponsor: Lundbeck
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 13

Back to Top


Location: Sunrise

Trial Title and Description: A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Enrolling
Study Dates: Start: October 2013 End: January 2017
Condition: Mild to Moderate Alzheimer's Disease
Age Eligibility: 55-85 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: III
Study Type: Interventional Allocation: Randomized
Sponsor: EnVivo
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.

Enrollment Status: Enrolling
Study Dates: Start: June 2012 End: September 2014
Condition: Mild to Moderate Alzheimer's disease with agitation
Age Eligibility: 50-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 200
Clinical Identifier: NCT01584440
Study Phase: II
Study Type: Interventional
Sponsor: Avanir
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Enrollment Status: Enrolling
Study Dates: Start: November 2012 End: December 2013
Condition: Mild to Moderate Alzheimer's with agitation
Age Eligibility: 50-88 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 400
Clinical Identifier: NCT01735630
Study Phase: II
Study Type: Interventional
Sponsor: Elan
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Enrollment Status: Enrolling
Study Dates: Start: December 2012 End: December 2016
Condition: Mild Cognitive Impairment/Early Alzheimer's disease
Age Eligibility: 50-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 800
Clinical Identifier: NCT01767311
Study Phase: II
Study Type: Interventional
Sponsor: Eisai
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Enrollment Status: Enrolling
Study Dates: Start: July 2013 End: December 2016
Condition: Mild Alzheimer's disease
Age Eligibility: 55-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 2100
Clinical Identifier: NCT01900665
Study Phase: III
Study Type: Interventional
Sponsor: Eli Lilly
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


For more information, connect with the Alzheimer’s Foundation of America’s licensed social workers. Click here or call 866.232.8484. Real People. Real Care.